Showing 1 to 2 of 2 results


mRNA-Based Immunotherapy Shows Promise, Potentially Lowering CAR-T Therapy Costs
A new mRNA-based immunotherapy treatment, developed by Carl June and colleagues at the University of Pennsylvania and Capstan, shows promise in treating autoimmune diseases and leukemia in preclinical trials, potentially lowering the cost to around €5,000 per dose.
mRNA-Based Immunotherapy Shows Promise, Potentially Lowering CAR-T Therapy Costs
A new mRNA-based immunotherapy treatment, developed by Carl June and colleagues at the University of Pennsylvania and Capstan, shows promise in treating autoimmune diseases and leukemia in preclinical trials, potentially lowering the cost to around €5,000 per dose.
Progress
48% Bias Score

Galapagos Restructures, Splits into Two, Cuts 300 Jobs
Galapagos, a Dutch-Belgian biotech firm facing financial struggles after setbacks in US market approvals, is splitting into two entities: one focusing on oncology cell therapy, and SpinCo, receiving \u20ac2.45 billion for acquisitions, resulting in 300 job cuts and separation from a restrictive agre...

Galapagos Restructures, Splits into Two, Cuts 300 Jobs
Galapagos, a Dutch-Belgian biotech firm facing financial struggles after setbacks in US market approvals, is splitting into two entities: one focusing on oncology cell therapy, and SpinCo, receiving \u20ac2.45 billion for acquisitions, resulting in 300 job cuts and separation from a restrictive agre...
Progress
40% Bias Score
Showing 1 to 2 of 2 results